Research
Energy balance
Semaglutide use is associated with a substantial decrease in long-term relative body weight of -12.1% compared to placebo.
Semaglutide can be considered an effective treatment option for weight loss in patients with obesity who do not have diabetes.
StrongSupportsmedium confidence
Compared to placebo, use of semaglutide was associated with substantial decreases in long-term relative (WMD: -12.1%; 95% CI -13.5, -10.7) and absolute body weight (WMD: -12.3 kg; 95% CI -13.6, -11.0).
Why this rating
Based on a systematic review and meta-analysis of randomized controlled trials.
Source
Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Areesha Moiz et al. · The American Journal of Cardiology · 2024
Meta-analysisCited 77×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →